Uli Alf Hacksell

Uli Alf Hacksell is currently an Independent Director at Active Biotech AB since 2019, a Director at Medivir AB since 2018, and a Director at Beactica Therapeutics.
Formerly, the roles included President, CEO, Director & Accounting Officer at ACADIA Pharmaceuticals, Inc. from 2014 to 2015, Chief Executive Officer at Acadia Pharmaceuticals AB from 2000 to 2015, Chairman at Action Pharma A, European Federation for Medicinal Chemistry, Adhera Therapeutics, Inc. from 2018 to 2020, Glionova AB, SynAct Pharma ApS, SynAct Pharma AB from 2023 to 2024, Annexin Pharmaceuticals AB, and Beactica Therapeutics AB. Other former positions include Director at Avalo Therapeutics, Inc. from 2019 to 2020, Independent Director at InDex Pharmaceuticals AB and Flerie AB, Vice President-Drug Discovery & Technology at Astra AB from 1991 to 1999, Professor at the University of Uppsala, President at Astra Draco AB, and VP-CNS Preclinical Research & Development at Astra Arcus AB in 1994.
Education includes a doctorate from the University of Uppsala.